These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16263590)

  • 21. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalidomide for the treatment of multiple myeloma.
    Hattori Y; Iguchi T
    Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome.
    Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y
    Jpn J Cancer Res; 2002 Sep; 93(9):1029-36. PubMed ID: 12359057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
    Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV
    Mayo Clin Proc; 2003 Jan; 78(1):34-9. PubMed ID: 12528875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
    Kastritis E; Dimopoulos M
    Leuk Lymphoma; 2007 Dec; 48(12):2295-7. PubMed ID: 18066998
    [No Abstract]   [Full Text] [Related]  

  • 27. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
    Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
    Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thalidomide-associated thrombocytopenia.
    Duyvendak M; Naunton M; Kingma BJ; Brouwers JR
    Ann Pharmacother; 2005 Nov; 39(11):1936-9. PubMed ID: 16219892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of blood morphology in patients with refractory multiple myeloma treated with thalidomide].
    Grzaśko N; Dmoszyńska A; Krawczyk S; Hus M; Soroka-Wojtaszko M; Ciepłuch H; Hellmann A
    Pol Arch Med Wewn; 2001 Jul; 106(1):573-9. PubMed ID: 11928568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
    Shah SR; Tran TM
    Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
    Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR
    Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Desirable and undesirable effects of thalidomide in patients with multiple myeloma].
    Foldyna D; Kamelander J; Krejcí M; Hájek R
    Vnitr Lek; 2003 Nov; 49(11):859-68. PubMed ID: 14689682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
    Offidani M; Corvatta L; Marconi M; Malerba L; Mele A; Olivieri A; Brunori M; Catarini M; Candela M; Capelli D; Montanari M; Rupoli S; Leoni P
    Eur J Haematol; 2004 Jun; 72(6):403-9. PubMed ID: 15128418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalidomide dosing in patients with relapsed or refractory multiple myeloma.
    Thompson JL; Hansen LA
    Ann Pharmacother; 2003 Apr; 37(4):571-6. PubMed ID: 12659617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Single-agent thalidomide for advanced and refractory multiple myeloma].
    Okikawa Y; Takimoto Y; Noda M; Imagawa J; Katayama Y; Sakai A; Okita H; Fujimura K; Kimura A
    Rinsho Ketsueki; 2003 Jun; 44(6):368-74. PubMed ID: 12884814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thalidomide in relapsed or refractory multiple myeloma: how much and for how long?
    Abdalla SH; Mahmoud S
    Leuk Lymphoma; 2003 Jun; 44(6):989-91. PubMed ID: 12854899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
    Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
    Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.
    Kodama T; Abe M; Iida S; Ozaki S; Sakai A; Sawamura M; Shimazaki C; Miyata A; Wakayama T; Murakami H
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):154-9. PubMed ID: 19406727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.